IGC · IGC Pharma Inc. Common Stock
View on chartInsiders & Stakes
| Bradbury Strategic Investment Fund A (Cayman Islands Registration No. CR-359857) 10% Owner | ▲ Buy | Grant | 13,823,529 Shares held | 3/22/2024 | View profile |
| Ram Mukunda CEO | ▼ Sell | Gift | 6,675,563 Shares held | 9/25/2026 | View profile |
| Claudia Grimaldi PFO | ▼ Sell | Gift | 3,271,092 Shares held | 9/25/2026 | View profile |
| Richard K. Prins Director | ▲ Buy | Option Exercise | 1,541,251 Shares held | 4/1/2026 | View profile |
| James P. Moran Director | ▲ Buy | Option Exercise | 1,235,735 Shares held | 4/1/2026 | View profile |
| Rohit Goel Senior Director of Finance&PAO | ▲ Buy | Grant | 235,000 Shares held | 5/13/2021 | View profile |
| John Edward LYNCH Director | ▲ Buy | Option Exercise | 134,401 Shares held | 6/1/2022 | View profile |
Transaction History
| Ram Mukunda | ▼ Sell | Gift | 100,000 | $0 | 9/25/2026 |
| Ram Mukunda | ▼ Sell | Gift | 100,000 | $0 | 9/25/2026 |
| Claudia Grimaldi | ▼ Sell | Gift | 150,000 | $0 | 9/25/2026 |
| Ram Mukunda | ▲ Buy | Grant | 2,226,475 | $601K | 6/30/2026 |
| Claudia Grimaldi | ▲ Buy | Grant | 2,048,378 | $553K | 6/30/2026 |
| Ram Mukunda | ▲ Buy | Option Exercise | 16,667 | $0 | 4/1/2026 |
| Ram Mukunda | ▲ Buy | Option Exercise | 33,332 | $0 | 4/1/2026 |
| James P. Moran | ▲ Buy | Option Exercise | 80,000 | $0 | 4/1/2026 |
| James P. Moran | ▲ Buy | Option Exercise | 50,000 | $0 | 4/1/2026 |
| Claudia Grimaldi | ▲ Buy | Option Exercise | 100,000 | $0 | 4/1/2026 |
| Claudia Grimaldi | ▲ Buy | Option Exercise | 138,462 | $36K | 4/1/2026 |
| Richard K. Prins | ▲ Buy | Option Exercise | 100,000 | $0 | 4/1/2026 |
| Richard K. Prins | ▲ Buy | Option Exercise | 70,000 | $0 | 4/1/2026 |
| Ram Mukunda | ▲ Buy | Option Exercise | 333,333 | $0 | 4/1/2026 |
| Ram Mukunda | ▲ Buy | Option Exercise | 323,077 | $84K | 4/1/2026 |
| Ram Mukunda | ▲ Buy | Option Exercise | 50,000 | $0 | 2/3/2026 |
| Richard K. Prins | ▲ Buy | Option Exercise | 100,000 | $0 | 1/19/2026 |
| Claudia Grimaldi | ▼ Sell | Gift | 50,000 | $0 | 10/17/2025 |
| Ram Mukunda | ▼ Sell | Gift | 100,000 | $0 | 10/17/2025 |
| James P. Moran | ▲ Buy | Open Market | 588,235 | $200K | 9/25/2024 |
| Richard K. Prins | ▼ Sell | Gift | 200,000 | $0 | 8/12/2024 |
| Bradbury Strategic Investment Fund A (Cayman Islands Registration No. CR-359857) | ▲ Buy | Grant | 8,823,529 | $3.0M | 3/22/2024 |
| Ram Mukunda | ▲ Buy | Option Exercise | 333,333 | $0 | 3/13/2024 |
| Ram Mukunda | ▲ Buy | Option Exercise | 233,334 | $0 | 3/13/2024 |
| Ram Mukunda | ▲ Buy | Option Exercise | 333,334 | $0 | 3/13/2024 |
| Ram Mukunda | ▲ Buy | Option Exercise | 251,250 | $0 | 3/13/2024 |
| Ram Mukunda | ▼ Sell | Gift | 200,000 | $0 | 3/13/2024 |
| Ram Mukunda | ▲ Buy | Option Exercise | 16,667 | $0 | 3/13/2024 |
| Ram Mukunda | ▲ Buy | Option Exercise | 16,667 | $0 | 3/13/2024 |
| Claudia Grimaldi | ▲ Buy | Option Exercise | 83,333 | $0 | 3/13/2024 |
| Claudia Grimaldi | ▲ Buy | Option Exercise | 58,333 | $0 | 3/13/2024 |
| Claudia Grimaldi | ▲ Buy | Option Exercise | 100,000 | $0 | 3/13/2024 |
| Claudia Grimaldi | ▲ Buy | Option Exercise | 95,000 | $0 | 3/13/2024 |
| Richard K. Prins | ▲ Buy | Option Exercise | 100,000 | $0 | 3/13/2024 |
| Richard K. Prins | ▲ Buy | Option Exercise | 58,333 | $0 | 3/13/2024 |
| Richard K. Prins | ▲ Buy | Option Exercise | 100,000 | $0 | 3/13/2024 |
| Richard K. Prins | ▲ Buy | Option Exercise | 42,750 | $0 | 3/13/2024 |
| Richard K. Prins | ▲ Buy | Option Exercise | 28,500 | $0 | 3/13/2024 |
| James P. Moran | ▲ Buy | Option Exercise | 50,000 | $0 | 3/13/2024 |
| James P. Moran | ▲ Buy | Option Exercise | 33,334 | $0 | 3/13/2024 |
| James P. Moran | ▲ Buy | Option Exercise | 80,000 | $0 | 3/13/2024 |
| James P. Moran | ▲ Buy | Option Exercise | 28,500 | $0 | 3/13/2024 |
| James P. Moran | ▲ Buy | Option Exercise | 29,000 | $0 | 3/13/2024 |
| Ram Mukunda | ▼ Sell | Gift | 400,000 | $0 | 6/23/2023 |
| Claudia Grimaldi | ▲ Buy | Option Exercise | 83,333 | $0 | 3/31/2023 |
| Claudia Grimaldi | ▲ Buy | Option Exercise | 58,334 | $0 | 3/31/2023 |
| James P. Moran | ▲ Buy | Option Exercise | 50,000 | $0 | 3/31/2023 |
| James P. Moran | ▲ Buy | Option Exercise | 33,334 | $0 | 3/31/2023 |
| Richard K. Prins | ▲ Buy | Option Exercise | 100,000 | $0 | 3/31/2023 |
| Richard K. Prins | ▲ Buy | Option Exercise | 58,334 | $0 | 3/31/2023 |
| Ram Mukunda | ▲ Buy | Option Exercise | 333,333 | $0 | 3/31/2023 |
| Ram Mukunda | ▲ Buy | Option Exercise | 233,334 | $0 | 3/31/2023 |
| Ram Mukunda | ▲ Buy | Option Exercise | 16,667 | $0 | 3/31/2023 |
| Ram Mukunda | ▲ Buy | Option Exercise | 16,667 | $0 | 3/31/2023 |
| John Edward LYNCH | ▲ Buy | Option Exercise | 9,375 | $0 | 6/1/2022 |
| Richard K. Prins | ▲ Buy | Option Exercise | 31,250 | $0 | 6/1/2022 |
| Claudia Grimaldi | ▲ Buy | Option Exercise | 9,375 | $0 | 6/1/2022 |
| Ram Mukunda | ▲ Buy | Option Exercise | 200,000 | $0 | 6/1/2022 |
| Richard K. Prins | ▲ Buy | Option Exercise | 93,750 | $0 | 5/31/2022 |
| John Edward LYNCH | ▲ Buy | Option Exercise | 28,125 | $0 | 5/31/2022 |
| Claudia Grimaldi | ▲ Buy | Option Exercise | 28,125 | $0 | 5/31/2022 |
| Ram Mukunda | ▲ Buy | Option Exercise | 600,000 | $0 | 5/31/2022 |
| Claudia Grimaldi | ▲ Buy | Option Exercise | 83,334 | $0 | 3/21/2022 |
| Richard K. Prins | ▲ Buy | Option Exercise | 100,000 | $0 | 3/21/2022 |
| Ram Mukunda | ▲ Buy | Option Exercise | 333,334 | $0 | 3/21/2022 |
| Ram Mukunda | ▲ Buy | Option Exercise | 16,667 | $0 | 3/21/2022 |
| James P. Moran | ▲ Buy | Grant | 50,000 | $0 | 1/18/2022 |
| James P. Moran | ▲ Buy | Grant | 100,000 | $0 | 1/18/2022 |
| Richard K. Prins | ▼ Sell | Gift | 40,000 | $0 | 12/23/2021 |
| Richard K. Prins | ▲ Buy | Grant | 300,000 | $0 | 12/20/2021 |
| Ram Mukunda | ▲ Buy | Grant | 0 | $0 | 12/20/2021 |
| Ram Mukunda | ▲ Buy | Grant | 0 | $0 | 12/20/2021 |
| Claudia Grimaldi | ▲ Buy | Grant | 250,000 | $0 | 12/20/2021 |
| Rohit Goel | ▲ Buy | Grant | 75,000 | $0 | 5/13/2021 |
| Richard K. Prins | ▲ Buy | Grant | 300,000 | $0 | 5/13/2021 |
| Ram Mukunda | ▲ Buy | Grant | 1,000,000 | $0 | 5/13/2021 |
| Ram Mukunda | ▲ Buy | Grant | 50,000 | $0 | 5/13/2021 |
| Richard K. Prins | ▼ Sell | Open Market | 50,000 | $88K | 3/9/2021 |
| Richard K. Prins | ▼ Sell | Open Market | 500 | $905 | 3/3/2021 |
| Richard K. Prins | ▼ Sell | Open Market | 49,500 | $89K | 3/3/2021 |
| Ram Mukunda | ▼ Sell | Open Market | 50,000 | $107K | 3/2/2021 |
| Richard K. Prins | ▼ Sell | Gift | 25,000 | $0 | 2/10/2021 |
| Richard K. Prins | ▼ Sell | Open Market | 50,000 | $102K | 12/1/2020 |
| Richard K. Prins | ▼ Sell | Gift | 20,000 | $0 | 11/9/2020 |
| Richard K. Prins | ▼ Sell | Gift | 13,000 | $0 | 10/13/2020 |
| Richard K. Prins | ▼ Sell | Gift | 60,000 | $0 | 8/13/2020 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
IGC Pharma Enters Phase 2 Alzheimer's Trial; DEA Hearing Paused
IGC Pharma has joined a Phase 2 study for its CALMA drug in Alzheimer’s disease, with results due in Q4 2026. Separately, a U.S. DEA judge paused a hearing on marijuana rescheduling after opponents cited a government report that highlighted gaps in federal procedures. The pause may affect the regulatory environment for cannabis‑derived products, while the trial marks a new development for IGC’s pipeline.
IGC Pharma Enters Phase 2 Alzheimer's Trial; DEA Hearing Paused. IGC Pharma has joined a Phase 2 study for its CALMA drug in Alzheimer’s disease, with results due in Q4 2026. Separately, a U.S. DEA judge paused a hearing on marijuana rescheduling after opponents cited a government report that highlighted gaps in federal procedures. The pause may affect the regulatory environment for cannabis‑derived products, while the trial marks a new development for IGC’s pipeline.